Inducing Potent and Durable T Cell Responses to Fight Disease
About this episode
Vaccitech first gained attention as co-inventor of the Covid-19 vaccine licensed to AstraZeneca. The University of Oxford spin-out is developing a pipeline of T cell immunotherapies to treat and cure chronic infectious diseases, autoimmune diseases, and cancers. The company’s lead experimental therapy is a potentially curative monotherapy for chronic hepatitis B viral infection. We spoke to Bill Enright, CEO of Vaccitech, about the company’s platform technologies, how they work, and how they enable the development of more effective immunotherapies.
Get every episode summarized
Each time The Bio Report publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The Bio Report
Resetting Severe Allergies at Their Cellular Source
The Bio Report
Innovating ADCs with Dual Targeting and Smarter Delivery
The Bio Report
Targeting the Brain’s Immune System in Alzheimer’s Disease
The Bio Report
How Gilead Is Building Durable Oncology and Immunology Franchises
The Bio Report